読み込み中
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
前日終値
$1.8352
−$0.0548 · -2.90%
日中の時刻はETです。市場データは遅延する場合があります。
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
日中レンジ
現在 $1.8352
52週レンジ
現在 $1.8352
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
36
割高
センチメント
53
まちまち
リスク
62
高リスク
モメンタム
19
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
日中レンジ
現在 $1.8352
52週レンジ
現在 $1.8352
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2026年度 | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|---|
| 売上高 | 445.3万 USD | 531.1万 USD | 541.5万 USD | 533.9万 USD | 1887.14万 USD |
| 売上原価 | 409.1万 USD | 481.3万 USD | 480.4万 USD | 489.3万 USD | 1589.4万 USD |
| 粗利益 | 36.2万 USD | 49.8万 USD | 61.1万 USD | 44.6万 USD | 297.74万 USD |
| 研究開発 | 78.8万 USD | 102.3万 USD | 149.1万 USD | 158.4万 USD | 181.24万 USD |
| 販売・一般管理 | 489.4万 USD | 461.2万 USD | 548.7万 USD | 608.5万 USD | 569.9万 USD |
| 営業費用 | 568.2万 USD | 563.5万 USD | 697.8万 USD | 766.9万 USD | 751.14万 USD |
| 受取利息 | 123.3万 USD | 16.5万 USD | 43.1万 USD | 13.3万 USD | 2.7万 USD |
| 減価償却費と償却費 | 42.1万 USD | 40万 USD | 37.4万 USD | 35.1万 USD | 59.48万 USD |
| 営業利益 | −532万 USD | −513.7万 USD | −636.7万 USD | −722.3万 USD | −453.4万 USD |
| 純利益 | −377.5万 USD | −497.3万 USD | −597.8万 USD | −714万 USD | −453.1万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
評価サンプルは3件と限定的です
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
